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With multiple options for urinary diversion after radical cystectomy for bladder cancer that have comparable cancer control
and complication rates, health-related quality of life (HRQOL) has become an important consideration. This article reviews the
methods for deﬁning HRQOL, the challenges in measuring HRQOL in bladder cancer, and the literature comparing HRQOL
after various methods ofurinary diversion.Recent contributions includethe validation ofHRQOL instruments speciﬁc to bladder
cancer and the publication of several prospective studies measuring HRQOL outcomes after cystectomy and urinary diversion.
There is no convincing evidence from existing literature that any particular method of urinary diversion oﬀers superior HRQOL
outcomes. Rather, there is growing evidence that good HRQOL can be achieved with patient education and consideration of
each patient’s clinical and psychosocial situation. Future research should utilize the validated bladder cancer speciﬁc HRQOL
instruments and perhaps explore the impact of preoperative counseling on postoperative HRQOL.
1.Introduction
In 2010 there were estimated 70,530 new cases of bladder
cancer in the United States, and over 500,000 current sur-
vivors [1, 2]. The standard of care in the United States for
muscle-invasive bladder cancer is radical cystoprostatectomy
for men and anterior exenteration for women. There is
also evidence that earlier cystectomy in high-risk superﬁcial
bladder cancer improves long-term survival [3]. Options
for urinary diversion after cystectomy include noncontinent
conduits, continent cutaneous diversions, and orthotopic
bladder substitutes. With the improvement of surgical tech-
nique in recent years, continent diversions and orthotopic
bladder substitutes have been shown to have similar peri-
operative complication rates, cancer control, and morbidity
[4, 5].
With the proliferation of urinary diversion options for
bladder cancer that have comparable cancer control and
complication rates, quality of life becomes an important
factor to consider. Health-related quality of life (HRQOL)
refers to the physical, psychological, and social domains of
health that are inﬂuenced by a person’s experiences, beliefs,
expectations, and perceptions [6]. The task of translating
the subjective components of health into a quantitative
value is a complex one, drawing from a variety of ﬁelds in
the social sciences. HRQOL is measured with questions, or
items, whose answers can be converted to numerical scores.
Many questionnaires, or instruments, have been developed
to assess the various aspects of HRQOL. An ideal instrument
should be valid (measures what it reports to measure),
reliable (able to give the same result on several occasions
given stable disease), and responsive (able to detect true but
clinically meaningful changes). The process of psychometric
and clinical testing is beyond the scope of this article, but
an instrument can only be correctly considered “validated”
if it has undergone the established rigors of developmental
testing so that its validity, reliability, and responsiveness can
be described quantitatively [7].
This article reviews the methods for deﬁning HRQOL,
the challenges in measuring HRQOL in bladder cancer
and the existing literature comparing HRQOL after various
methods of urinary diversion.2 Advances in Urology
2.MeasuringHRQOL
HRQOL instruments can be either generic or disease-spe-
cific. Generic instruments are applicable to all patients re-
gardless of their illness. They may address issues like bodily
pain, energy or fatigue, and limitations in physical activity
that are common to many disease processes. Examples of
generic instruments are the Medical Outcomes Study 36-
Item Short Form (SF-36) [8]a n dt h eS i c k n e s sI m p a c tP r o ﬁ l e
(SIP) [9].
Therearemultipleinstrumentsthatassess cancer-speciﬁc
HRQOL, including the European Organization for Research
andTreatmentofCancer-QOL(EORTC-QLQ-C30)[10]and
the Functional Assessment of Cancer Therapy general form
(FACT-G) [11]. The current version of the EORTC-QLQ-
C30 contains 30 items that are grouped into ﬁve functional
scales (physical, role, emotional, cognitive, and social),
three symptoms scales (fatigue, nausea and vomiting, and
pain), and an overall HRQOL scale. The broadness of this
instrument makes it generally applicable to all cancer states,
but it lacks the speciﬁcity to address issues that may be
unique to a particular type of cancer [12].
Disease-speciﬁc instruments focus on the issues that are
relevant to patients with a particular disease state. Some dis-
ease-speciﬁc instruments are developed from validated
generic instruments, with additional items added to make
them more speciﬁc to the disease of interest. Forexample, 12
items focusing on urinary tract symptoms, intestinal symp-
toms, sexual symptoms, and stoma concerns were added
to the FACT-G to create the FACT-BL, designed to address
HRQOL in bladder cancer. Likewise, 17 items were added
to the FACT-G questionnaire to create the Vanderbilt
Cystectomy Index (FACT-VCI), which has been separately
validated to measure HRQOL following radical cystectomy
and urinary diversion for bladder cancer [13]. The Euro-
pean Organization for Research and Treatment of Cancer
(EORTC)hasalsoaddeditemstotheEORTC-QLQ-C30core
questionnaire to make it speciﬁc for superﬁcial and invasive
bladder cancer, and is in the process of validating these
instruments [14]. More recently, the Bladder Cancer Index
(BCI) has been developed and validated to assess health
outcomes speciﬁc to localized bladder cancer [15]. Refer to
Table 1 for a comparison of bladder cancer speciﬁc HRQOL
instruments.
3.ChallengesofMeasuringHRQOL in
BladderCancer
Measuring HRQOL in bladder cancer has its unique diﬃ-
culties. All of the currently available bladder cancer-speciﬁc
instruments contain items evaluating the urinary domain,
but the items mostly address general problems with urinary
control (e.g., “I have trouble controlling my urine” or “I
u r i n a t em o r ef r e q u e n t l yt h a nu s u a l ” ) .L e a k i n gf r o mas t o m a ,
however, may be a very diﬀerent experience than leaking per
urethra. Diﬀerent diversions also come with a diﬀerent set
of potential side eﬀects (e.g., metabolic derangements) and
impact on body image. It is diﬃcult to account for all these
factors in a single questionnaire that can be applied to all
patients with bladder cancer.
Consequently, many of the bladder cancer-speciﬁc in-
struments target an even narrower population of bladder
cancer patients. As shown in Table 1,t h eE O R T CQ L Q -
BLS24 is targeted to superﬁcial bladder cancer and will in-
clude items related to the bother of repeated cystoscopies,
whereas the FACT-VCI was validated to target patients who
undergo radical cystectomy for bladder cancer.
In addition, sexual function is an important domain
when discussing the impact of bladder cancer and its treat-
ment. Since men and women experience diﬀerent issues
related to sexual function, it is challenging to create a ques-
tionnaire that is applicable to both sexes. The BCI sexual
domain asks gender-neutral questions addressing sexual
desire and arousal, ability to climax, and genital sensation.
Butmenmayexperienceissueswitherectionandejaculation,
while women may have problems with vaginal lubrication
and dyspareunia, which even a disease-speciﬁc instrument
liketheBCIwouldnotbespeciﬁcenoughtodistinguish [16].
On the other hand, as instruments are tailored more
speciﬁcally to the disease of interest, they may be less likely
to detect unanticipated eﬀects of the disease. For example,
the BCI contains 36 items distributed among the 3 primary
domains that are expected to be relevant in bladder cancer:
urinary, bowel, and sexual. If a treatment for localized
bladder cancer were to unexpectedly cause a neurologic side
eﬀect, this disease-speciﬁc instrument would not be sensitive
enough to detect this change.
4.CurrentLiterature:HRQOLafterCystectomy
In 2005, Porter and Penson published a systematic review
examining HRQOL outcomes among diﬀerent types of uri-
nary diversion after radical cystectomy [17]. After excluding
studies that did not speciﬁcally address bladder cancer pa-
tients, studies that included radiotherapy as treatment, and
studies that did not compare at least 2 types of urinary
diversion (ileal conduit, orthotopic neobladder, or continent
cutaneousurinary reservoir), 15 studieswere appropriatefor
analysis. The review found no randomized, controlled stud-
ies. Only 1 study was performed prospectively and included
preoperative baseline measurements [18]. The other studies
were cross-sectional, consisting of a single-mailed or clinic-
administered instrument. Of 15 studies, 10 (67%) used a
previously validated health-related qualityoflife instrument,
while 10 (67%) used an instrument developed by the inves-
tigators without previous validation, either in conjunction
with a validated instrument or as the sole measure of quality
of life. The authors concluded that the available data did not
conclusively show that any form of urinary diversion was
superior to another in terms of HRQOL.
Theyalso notedthatlimitations totheliteratureincluded
the lack of baseline assessment before cystectomy, the lack of
longitudinal data to evaluate the impact over time, and the
lack of a bladder cancer-speciﬁc and validated instrument to
measure quality of life. Despite the inability to draw conclu-
sions regarding the superiority of any method of diversionAdvances in Urology 3
Table 1: Comparison of bladder cancer speciﬁc HRQOL instruments.
Target population No of items Domains Validation
General
well-being
Bowel
(no. of items)
Urinary
(no. of items)
Sexual
(no. of items)
Bladder
Cancer Index
(BCI)
Localized bladder
cancer 36 No Yes (10) Yes (14) Yes (12)
Test-retest 0.73–0.95,
internal consistency
0.77–0.91
EORTC
QLQ-BLS24
Superﬁcial bladder
cancer (Ta, T1,
CIS)
24 No Yes
Yes (including items
related to intravesical
treatment: fever, malaise,
bother of repeated
cystoscopies)
Yes Pending
EORTC
QLQ-BLM30
Invasive bladder
cancer (T2, T3,
T4a/b)
30 No Yes
Yes (including items
related to urostomy
probems,
catheterization)
Yes Pending
FACT-BL Bladder cancer 45 FACT-G Yes (4) Yes (3) + Stoma (2) Yes (2) FACT-G: test-retest
0.82–0.92
FACT-VCI
Bladder cancer,
after radical
cystectomy
45 FACT-G Yes (4) Yes (4) Yes (4)
Test-retest 0.79,
internal consistency
0.83–0.85
after cystectomy, some common patterns were identiﬁed
across the studies that may help future research. Three
studies indicated that urinary leakage was more ofa problem
with conduit diversion than with continent diversion [19–
21]. Three studies indicated that patients with neobladder or
continent reservoir were more likely to travel than patients
with conduit diversion [22–24]. Two studies indicated that
patients with continent diversions scored better on social
function domains than those with conduit diversions [25,
26].
In 2005,Gerharz etal.publisheda reviewthatratedstud-
ies by levels of evidence and grades of recommendations set
outby the International Consultation on UrologicalDiseases
modiﬁcation of the Oxford Centre for Evidence-Based
Medicine [27]. They identiﬁed no studies with level I evi-
denceand alsoconcludedthat therewas no evidencetoclaim
that continent reconstruction provides better quality of life
than conduit diversion.
Since the publication of these reviews, there have been a
handful of studies published in the last 5 years that evaluate
HRQOL after cystectomy in bladder cancer. In 2007 Gilbert
et al. used the recently validated bladder cancer-speciﬁc
instrument, the Bladder Cancer Index (BCI), to assess
HRQOL in patients treated with a variety of interventions,
including cystectomy and endoscopic procedures [28]. They
identiﬁed all bladder cancer patients in an institutional
bladder cancer database from a high-volume tertiary referral
center. From this population, 315 (45%) completed the BCI
and were included in the study. There was no pretreatment
HRQOL assessment. The cases were stratiﬁed into 4 groups
according to treatment type: native bladder without intrav-
esical treatment, native bladder with intravesical treatment,
cystectomy with ileal conduit, and cystectomy with ortho-
topic neobladder. They found that cystectomy groups scored
relatively lowerthan native bladdergroupsin all the function
and bother domains (urinary, bowel, sexual). Interestingly,
the cystectomy with orthotopic neobladder group scored
signiﬁcantlylowerinurinary functionscoresthantheother3
groups, challenging the commonly held belief that continent
urinary diversion oﬀers improved HRQOL outcomes com-
pared to incontinent diversion. However, despite the diﬀer-
ence in functional scores, the urinary bother scores did not
diﬀer between the cystectomy groups, leading the authors
to speculate that perhaps neobladder patients are willing to
compromise physiologic urinary function in exchange for
anatomic urinary function.
Two recent prospective studies looked at body image and
its impact of HRQOL. In 2009 Somani et al. published the
results of a study that prospectively evaluated 32 patients
undergoing radical cystectomy for bladder cancer; 29 ileal
conduit diversions and 3 neobladder replacements were per-
formed [29]. The study evaluated HRQOL preoperatively
and 9–12 months after cystectomy and urinary diversion
using the SEIQoL-DW, a validated generic instrument
administered by an independent researcher, and the EORTC
QLQ-C30. Patients identiﬁed several nonhealth-related de-
terminants of quality of life (family, relationships, ﬁnance)
that were most important. None of the patients mentioned
body image as an important determinant of quality of life.
When asked speciﬁcally about appearance, 76% in the ileal
conduit diversion group said that it was quite or very impor-
tant but only 14% thought that it would change signiﬁcantly
after the operation.
In a separate prospective study, Hedgepeth et al. evalu-
ated changes in body image and quality oflife in 139 patients
undergoing neobladder replacement after cystectomy and
85 patients undergoing ileal conduit diversion, compared
to a reference group of patients who had cystoscopy [30].
HRQOL outcomes were measured using the Bladder Cancer
Index (BCI),which consistsof36questionscoveringurinary,4 Advances in Urology
bowel, and sexual health domains. Function is measured by
items describing frequency and control of bodily or stoma
function, and bother is measured by items describing how
much a patient is troubled by their symptoms. Participants
were assessed preoperatively, as well as at several time points
in the 8 years after surgery. The authors concluded that
patientswith continenturinary diversionsexperience greater
functional urinary impairment with little diﬀerence in over-
all bother. Body image for both neobladder and ileal conduit
diversion patients worsened immediately after surgery but
improved in a linear fashion over time. Ileal conduit diver-
sion patients eventually returned to baseline body image
levels, with no signiﬁcant diﬀerence from the cystoscopy
group in the long-term. Neobladder patients never returned
to baseline body image levels.
Acknowledging that the sociocultural milieu in which
patients live can inﬂuence their perception of health and
illness, studies have also begun to explore the role of cultural
diﬀerences in HRQOL. In a 2007 prospective study com-
paring male patients from Sweden and Egypt undergoing
radical cystectomy and orthotopic neobladder substitution
for locally advanced bladder cancer, M˚ ansson et al. reported
that Egyptian men were more likely to express depression
and anxiety on the Hospital Anxiety and Depression Scale
(HADS), a validated generic instrument to detect mood
disorders, as well as score lower on the FACT-BL than their
Swedish counterparts [31]. The authors did warn against
pitfalls in comparing patients from diﬀerent cultural groups,
such as the inherent demographic diﬀerences that may bias
the results, as well as the diﬃculty of preserving concep-
tual and linguistic equivalence when translating HRQOL
questions into a diﬀerent language. However, this represents
an important step in acknowledging that patient-assessed
outcomesdiﬀerinpatientsfromdiﬀerentsocioculturalback-
grounds.
Investigators are also beginning to evaluate HRQOL in
patients undergoing bladder preservation therapy in the set-
ting of invasive bladder cancer. Lagrange et al. in a prospec-
tive, multicenter study published this year evaluated 53 pa-
tients with muscle-invasive disease in a Phase II trial who
underwent pelvic radiation and concurrent chemotherapy
with cisplatin and 5-ﬂuorouracil [32]. Subjects completed
the EORTC QLQ-C30 pretreatment, as well as at several
time points post treatment. The results indicated that 70%
maintained good scores for bladder function for 24 months,
atwhich pointdeteriorationin symptoms, suchasfrequency,
pain, and urinary control, was seen. This study is limited by
the lack of a disease-speciﬁc instrument, and there are not
yet any studies comparing HRQOL in bladder preservation
therapy with the standard of care, cystectomy with urinary
diversion.
5.Conclusion
Improvements have been made in recent years in the ﬁeld of
HRQOLresearch inbladdercancer.Moreprospectivestudies
are being published with HRQOL instruments administered
prior to treatment as well as at multiple points in time after
treatment. However, the vast majority of available studiesare
still retrospective and cross-sectional. This study design is
less able to distinguish diﬀerences in health status that may
simply reﬂect underlying preoperative diﬀerences.
Another major limitation to existing literature is the lack
of an available bladder cancer-speciﬁc, validated instrument
to measure health-related quality of life. With the develop-
ment of the Bladder Cancer Index, as well as the growing
popularityoftheFACT-BLand thebladdercancermoduleof
theEORTCQLQ-C30,researchers shouldbebetterequipped
to assess HRQOL in bladder cancer patients.
Even with the improvements of the last 5 years, there is
still not conclusive evidence that any type of urinary
diversion oﬀers superior HRQOL outcomes. In fact, though
postcystectomy patients commonly experience urinary and
sexual problems, HRQOL remains good irrespective of the
method of urinary diversion. It has been speculated that the
r e a s o nf o rt h i sﬁ n d i n gi st h a tp a t i e n t sw h or e c e i v et h o r o u g h
preoperative counseling end up choosing the method that
is most suitable for them and are well prepared for the
adjustment after surgery [27]. It seems that patient educa-
tion, careful evaluation of each patient’s unique clinical and
psychosocial situation, and active patient participation in
treatment decisions remain crucial to good postoperative
quality of life.
Although progress has been made in evaluating HRQOL
in postcystectomy bladder cancer patients, there is still a
need for well-designed, prospective studies. In light of recent
evidence demonstrating that despite marked diﬀerences in
functional outcomes, body image and ultimately overall
bother are similar between methods of urinary diversion,
it would be interesting to conduct studies looking at the
way preoperative counseling and patient education impact
HRQOL post treatment.
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